TREMFYA (guselkumab), interleukin 23 inhibitor immunosuppressant

High clinical benefit for the treatment of severe chronic plaque psoriasis in adults defined by:

• failure of at least two treatments including non-biological systemic treatments and light therapy

• and an extensive form and/or significant psychosocial impact

but no demonstrated clinical improvement compared to other anti-interleukins.

Insufficient clinical benefit to justify reimbursement for other forms.

• TREMFYA has MA for the treatment of moderate to severe plaque psoriasis in adults, requiring systemic treatment.

• It has demonstrated its superiority over HUMIRA (adalimumab).

• TREMFYA is a second-line systemic treatment to be reserved for adults with severe chronic plaque psoriasis, defined by:

• failure (insufficient response, contraindication or intolerance) of at least two treatments including non-biological systemic treatments and light therapy

• and an extensive form and/or with significant psychosocial impact.